EVALUATION OF THE HEPATITIS B THERAPEUTIC VACCINE CANDIDATE CLB-3000 (CLB-405 + CLB-505 WITH ALHYDROGEL): A 9- OR 15-WEEK TOXICITY STUDY IN NEW ZEALAND WHITE (NZW) RABBITS WITH A 4-WEEK RECOVERY PERIOD

CLB-3000 - ClearB Therap

Aileen Rubio, CEO, Clearb Therapeutics, Inc.; Clearb Therapeutics; Laurie Iciek, Nonclinical, Biologics Consulting

Oct 23, 2022